Health news
The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application for Vaxneuvance (pneumococcal 15-valent conjugate vaccine) for the prevention of invasive pneumococcal disease in pediatric patients 6 weeks through 17 years of…
The Food and Drug Administration (FDA)’s Vaccines and Related Biological Products Advisory Committee voted 21 to 0 (with 1 abstention) in favor of recommending Emergency Use Authorization (EUA) for the Novavax COVID-19 vaccine (NVX-CoV2373) for…
The Food and Drug Administration (FDA) has approved Priorix (measles, mumps and rubella vaccine, live) for active immunization for the prevention of measles, mumps and rubella in individuals 12 months of age and older. Priorix…
The Food and Drug Administration (FDA) has approved Priorix (measles, mumps and rubella vaccine, live) for active immunization for the prevention of measles, mumps and rubella in individuals 12 months of age and older. Priorix…
Policy reforms and legislation to enhance the authority of pharmacists to administer vaccines may lead to increased immunization rates among individuals in low-income communities, especially older adults. These findings were published in the Journal of…
Although the spotlight has been on the COVID-19 pandemic during the past few years, attention has turned toward the recent outbreak of monkeypox. First observed among humans in 1970 during efforts to eradicate variola virus…
The Food and Drug Administration (FDA) has authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine as a single booster dose to be administered to individuals 5 to 11 years of age at least 5…
The aluminum phosphate-adjuvanted inactivated enterovirus 71 (EV71) vaccine was highly effective for the prevention of EV71-associated infections among infants and children. These findings, from a phase 3 trial, were published in The Lancet. This prospective,…
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to RSVpreF (PF-06928316), a respiratory syncytial virus (RSV) vaccine candidate, for the prevention of lower respiratory tract disease caused by RSV in adults 60…
Positive interim data from the phase 2/3 study evaluating the Moderna COVID-19 vaccine, mRNA-1273, in children 6 months to less than 6 years of age showed a robust neutralizing antibody response. The randomized, observer-blind, placebo-controlled…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021